Goldman Sachs Group Inc Akebia Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $780 Billion
  • Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,767,813 shares of AKBA stock, worth $3.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,767,813
Previous 3,934,002 55.06%
Holding current value
$3.01 Million
Previous $14.3 Million 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
$2.7 - $4.01 $5.85 Million - $8.69 Million
-2,166,189 Reduced 55.06%
1,767,813 $4.77 Million
Q2 2025

Aug 14, 2025
BUY
$1.55 - $3.97 $1.87 Million - $4.8 Million
1,209,563 Added 44.4%
3,934,002 $14.3 Million
Q1 2025

May 09, 2025
BUY
$1.69 - $2.84 $2.91 Million - $4.89 Million
1,722,245 Added 171.85%
2,724,439 $5.23 Million
Q4 2024

Feb 11, 2025
BUY
$1.26 - $2.13 $651,325 - $1.1 Million
516,925 Added 106.52%
1,002,194 $1.86 Million
Q3 2024

Nov 14, 2024
BUY
$0.94 - $1.55 $128,169 - $211,344
136,351 Added 39.08%
485,269 $640,000
Q2 2024

Aug 13, 2024
SELL
$0.86 - $1.63 $915,672 - $1.74 Million
-1,064,735 Reduced 75.32%
348,918 $355,000
Q1 2024

May 15, 2024
BUY
$1.27 - $2.24 $1.7 Million - $3.01 Million
1,342,452 Added 1885.44%
1,413,653 $2.59 Million
Q4 2023

Feb 13, 2024
BUY
$0.8 - $1.28 $56,960 - $91,137
71,201 New
71,201 $88,000
Q2 2023

May 14, 2024
SELL
$0.51 - $1.43 $25,281 - $70,886
-49,571 Reduced 73.07%
18,273 $16,000
Q2 2023

Aug 14, 2023
SELL
$0.51 - $1.43 $25,281 - $70,886
-49,571 Reduced 73.07%
18,273 $16,000
Q1 2023

May 14, 2024
BUY
$0.56 - $1.15 $29,408 - $60,393
52,516 Added 342.61%
67,844 $37,000
Q1 2023

May 11, 2023
BUY
$0.56 - $1.15 $29,408 - $60,393
52,516 Added 342.61%
67,844 $37,000
Q4 2022

May 14, 2024
SELL
$0.25 - $0.58 $112,120 - $260,119
-448,482 Reduced 96.7%
15,328 $8,000
Q4 2022

Feb 13, 2023
SELL
$0.25 - $0.58 $112,120 - $260,119
-448,482 Reduced 96.7%
15,328 $8,000
Q3 2022

May 14, 2024
BUY
$0.3 - $0.46 $36,679 - $56,241
122,264 Added 35.8%
463,810 $147,000
Q3 2022

Nov 10, 2022
BUY
$0.3 - $0.46 $36,679 - $56,241
122,264 Added 35.8%
463,810 $0
Q2 2022

May 14, 2024
BUY
$0.32 - $0.67 $86,510 - $181,131
270,345 Added 379.69%
341,546 $0
Q2 2022

Aug 15, 2022
SELL
$0.32 - $0.67 $179,014 - $374,812
-559,421 Reduced 62.09%
341,546 $120,000
Q1 2022

May 16, 2022
SELL
$0.72 - $2.93 $897,261 - $3.65 Million
-1,246,196 Reduced 58.04%
900,967 $647,000
Q4 2021

Feb 14, 2022
BUY
$2.26 - $3.34 $3.69 Million - $5.45 Million
1,632,905 Added 317.53%
2,147,163 $4.85 Million
Q3 2021

Nov 10, 2021
BUY
$2.35 - $3.88 $1.21 Million - $2 Million
514,258 New
514,258 $1.48 Million

Others Institutions Holding AKBA

# of Institutions
191
Shares Held
121M
Call Options Held
267K
Put Options Held
280K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $313M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email